Simultaneous Quantification of Antidiabetic Agents in Human Plasma by a UPLC–QToF-MS Method

Mariana Millan Fachi, Letícia Bonancio Cerqueira, Letícia Paula Leonart, Thais Martins Guimarães de Francisco, Roberto Pontarolo

Department of Pharmacy, Federal University of Paraná, Curitiba – Paraná, Brazil

*pontarolo@ufpr.br

Abstract

An ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry method for the simultaneous quantification of chlorpropamide, glibenclamide, gliclazide, gimepiride, metformin, nateglinide, pioglitazone, rosiglitazone, and vildagliptin in human plasma was developed and validated, using isoniazid and sulfaquinoxaline as internal standards. Following plasma protein precipitation using acetonitrile with 1% formic acid, chromatographic separation was performed on a cyano column using gradient elution with water and acetonitrile, both containing 0.1% formic acid. Detection was performed in a quadrupole time-of-flight analyzer, using electrospray ionization operated in the positive mode. Data from validation studies demonstrated that the new method is highly sensitive, selective, precise (RSD < 10%), accurate (RE < 12%), linear (r > 0.99), free of matrix and has no residual effects. The developed method was successfully applied to volunteers’ plasma samples. Hence, this method was demonstrated to be appropriate for clinical monitoring of antidiabetic agents.

Introduction

Diabetes mellitus is characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both [1, 2]. It is considered one of the most worrisome health problems, affecting 415 million people worldwide, which is projected to increase to 642 million people by the year 2040 [3].

In order to achieve glycemic control in type 2 diabetes (T2D), it is initially recommended that patients maintain a healthy diet and engage in regular physical activity [4]. When lifestyle modification alone is not enough to achieve glycemic targets, oral antidiabetic agents are prescribed [5].

Metformin, a drug from the biguanide class, is typically the first-line therapy used to control T2D because of its efficacy, durability, low cost, and ability to prevent weight gain and reduce risk of hypoglycemia. However, for patients with a high HbA1c level (i.e., HbA1c ≥ 9.0) or for nonresponders to metformin after three months of treatment, the use of a second oral agent is recommended [6–10].
There are several possible combinations of antidiabetic agents; the choice of therapy is based on the individual characteristics of the patient, the pharmacological properties of the drug, and the availability of the therapy in the market, which can vary from country to country [11–13].

The choice for a second agent to be used along with metformin can be established by following the recommendations of the American Association of Clinical Endocrinologists and American College of Endocrinology [7], the American Diabetes Association and the European Association for the Study of Diabetes [8, 14], and the Sociedade Brasileira de Diabetes (Brazilian Society of Diabetes) [9]. It is recommended that metformin be combined with an agent of one of these therapeutic classes: sulfonylurea, thiazolidinedione, or DPP-4 inhibitors. Besides these classes, meglitinides can be used for postprandial glucose control [8].

Measurement of the plasma concentration of antidiabetic agents through a bioanalytical method is important for therapeutic monitoring and for evaluating adherence to therapy, pharmacokinetic aspects of the drug, and dosing optimization [15, 16].

Several bioanalytical methods for the quantification of antidiabetic agents in plasma have been reported in the literature; however, these methods are used for few drugs and are not suitable for the different combinations commonly used in clinical practice. In the present study, a fast and sensitive ultra-performance liquid chromatography quadrupole time of flight mass spectrometry (UPLC-QToF-MS) method was developed and validated according to the guidelines of the European Medicines Agency [17], U.S. Food and Drug Administration [18], and Brazil National Health Surveillance Agency [19]. This method was used to simultaneously quantify the levels of chlorpropamide, glibenclamide, gliclazide, glimepiride, metformin, nateglinide, pioglitazone, rosiglitazone, and vildagliptin in human plasma.

Materials and Methods

Reagents and Samples

High-performance liquid chromatography (HPLC) grade acetonitrile and methanol were obtained from Panreac (Barcelona, Spain). Formic acid (88%) was obtained from J.T. Baker (New Jersey, USA), and ammonium formate (97%) was obtained from Spectrum Chemical (Gardena, EUA). Ultrapure water was produced using a purification system from Millipore Corporation, USA.

The metformin (99.7%), glibenclamide (99.0%), and glimepiride (99.4%) standards were purchased from United States Pharmacopoeia (Rockville, USA). Standards of chlorpropamide (99.9%), gliclazide (100.0%), and isoniazid (99.5%), which was used as the internal standard (IS), were obtained from Fiocruz/INCQS (Rio de Janeiro, Brazil). Standards of nateglinide (98.0%), pioglitazone (98.0%), rosiglitazone (98.0%), and sulfaquinoxaline (96.0%), which was used as the IS, were supplied by Sigma–Aldrich (St. Louis, USA). The vildagliptin (98.0%) standard was acquired from Ontario Chemicals (Ontario, Canada). The internal standards were selected based on their structural similarity to the analytes. The structure of each substance is shown in Fig 1.

Normal, hemolyzed, and lipemic blank plasmas were provided by the Center of Hematology of Paraná, Hemepar, Curitiba, Brazil. After centrifugation at 4,000 rpm at room temperature, the plasma was collected and stored at −40°C.

Preparation of stock and working solutions

Stock solutions of chlorpropamide (CHL), glibenclamide (GBC), gliclazide (GCZ), glimepiride (GMP), metformin (MET), nateglinide (NAT), pioglitazone (PIO), rosiglitazone (ROS), vildagliptin (VDP), and ISs were prepared individually using acetonitrile:methanol (80:20, v/v), in
order to obtain concentrations of 1 mg.mL\(^{-1}\) of each analyte. All stock solutions were stored in amber bottles at \(-40^\circ\text{C}\). Working standard solutions were freshly prepared every day from the stock solutions for each experiment, through appropriate dilution with acetonitrile:water (70:30, v/v), to achieve the concentrations of 1, 10 and 100 \(\mu\text{g.mL}^{-1}\) of analytes and ISs.

**Liquid Chromatography**

Chromatography was conducted on an Acquity UPLC H-Class system (Waters Corp., Milford, USA) equipped with an autosampler (Sample Manager FTN, Waters Corp., Milford, USA) maintained at room temperature. The separation of analytes was performed on an Acquity UPLC\(^{\text{TM}}\) HSS Cyano (100 x 2.1 mm, 1.8 \(\mu\text{m}\)) from Waters Corp. (Dublin, Ireland). The column temperature was maintained at 40\(^\circ\text{C}\). The analysis was performed with gradient elution using water and acetonitrile (both containing 0.1% formic acid) as mobile phases A and B, respectively. The elution order was as follows: 0–0.50 min, 2% B; 0.50–3.50 min, 2% to 70% B; 3.50–
3.51 min, 70% to 95% B; 3.51–4.50, maintained at 95% B; 4.50–4.51 min, 95% to 2% B; and 4.51–6.50 min, maintained at 2%. The flow rate was 600 μL.min⁻¹ and the injection volume was 5 μL.

The Waters Xevo G2-S QToF mass spectrometer (Waters Corp., Milford, USA) was connected to the UPLC system via an electrospray ionization (ESI) interface. The ESI source was performed in positive ionization mode with a capillary voltage of 0.4 kV. The temperature of the source was set at 150 °C, and the desolvation temperature was set at 500 °C. Nitrogen was used as the cone and desolvation gas. The cone gas flow was 50 L.h⁻¹, and the desolvation gas flow was 800 L.h⁻¹. All data was collected in centroid mode, acquired using MassLynx™ NT4.1 software, and processed using QuanLynx software (Waters Corp., Milford, USA).

Mass Spectrometry

Mass spectrometry data was collected over a mass range of 50–600 m/z. The MS experiment was carried out under the following conditions: function 1, collision energy of 4 V. Accurate mass was determined with a 1000 ng.mL⁻¹ leucine enkephalin (m/z 556.2771 [M+H]⁺) solution at a flow rate of 20 μL.min⁻¹, which was used for lockmass. The interval mass considered in the procedure was lower than 5 ppm.

Quantification was performed using high-resolution mass data of the molecular ions [M +H]⁺ at m/z values of 277.0413 (chlorpropamide) (medium mass error 1.08 ppm), 494.1516 (glibenclamide) (medium mass error 0.80 ppm), 324.1381 (gliclazide) (medium mass error 1.23 ppm), 491.2328 (glimepiride) (medium mass error 1.62 ppm), 130.1092 (metformin) (medium mass error 0.76 ppm), 318.2068 (nateglinide) (medium mass error 0.62 ppm), 357.1373 (pioglitazone) (medium mass error 1.27 ppm), 358.1225 (rosiglitazone) (medium mass error 1.94 ppm), 304.2025 (vildagliptin) (medium mass error 1.31 ppm), 138.0667 (isoniazid-IS) (medium mass error 1.62 ppm), and 301.0759 (sulfaquinoxaline-IS) (medium mass error 0.33 ppm).

Sample preparation

The frozen plasma samples were thawed at room temperature prior to analysis. Aliquots of 200 μL of blank plasma (plasma free of analytes and IS) were transferred to 2 mL plastic centrifuge tubes. Fifty microliters of the analytes working solutions were spiked into the plasma samples to achieve concentrations within the ranges of the calibration curve and quality control samples (concentration of the spiking solution for the standards are demonstrated in S1 Table). Fifty microliters of the ISs intermediate standard solution, in the concentration of 1500 ng.mL⁻¹ for sulfaquinoxaline and 4000 ng mL⁻¹ for isoniazid, were also added to the plasma samples, in order to obtain a fixed concentration of 75 ng.mL⁻¹ sulfaquinoxaline and 200 ng mL⁻¹ isoniazid. The samples were placed on a vortex for 1 min. Then, 700 μL of acetonitrile (containing 0.1% formic acid) was added to the tube, and the samples were shaken again for 3 min. Samples were centrifuged at 14,000 rpm and 4 °C for 10 min (Eppendorf 5810R, Hamburg, Germany), and 500 μL of supernatant was transferred to 2.0 mL glass vials and diluted to 1:2 (v/v) with ultrapure water. Then, the samples were centrifuged once more at 4,000 rpm and 4 °C for 10 min, and placed into an autosampler rack for injection into the chromatographic system.

Method validation

The method was validated for the parameters of limit of detection (LOD), lower limit of quantification (LLOQ), selectivity, calibration curve, precision, accuracy, carry-over, recovery,
matrix effect, and stability according to FDA, EMA, and ANVISA guidelines for bioanalytical method validation [17–19].

**Limit of detection (LOD) and lower limit of quantification (LLOQ).** The limits of detection and quantification were determined according to a signal-to-noise ratio of 3:1 for LOD and at least 5:1 for LLOQ. Plasma samples were spiked in triplicate with decreasing concentrations of analytes, until the lowest concentration with desired precision (RSD < 20%) was achieved.

**Selectivity.** Six blank plasma samples (free of analytes and IS) from different sources (four normal, one lipemic, and one hemolyzed plasma) were compared to a plasma sample spiked with analytes (at LLOQ concentrations) and IS.

**Calibration curve.** Calibration curves were constructed for three consecutive days using internal standards. The range of the calibration curve was based on therapeutic range and plasma concentration of antidiabetic agents found in others studies in literature [20–31]. Eight concentration levels of analytes were prepared in triplicate from serial dilutions of working solutions of NAT, PIO, and ROS. Nine concentration levels of analytes were prepared in triplicate from serial dilutions of working solutions of CHL, GBC, GCZ, GMP, MET, and VDP. The calibration curves contained a blank plasma sample (processed matrix sample without IS) and a zero sample (processed matrix sample with IS). The concentration ranges obtained for each analyte were as follows: 50–1000 ng.mL\(^{-1}\) for GCZ; 125–1000 ng.mL\(^{-1}\) for ROS; 125–2000 ng.mL\(^{-1}\) for GBC, GMP, and VDP; 250–2000 ng.mL\(^{-1}\) for PIO; 250–4000 ng.mL\(^{-1}\) for MET; 500–4000 ng.mL\(^{-1}\) for NAT; and 500–4500 ng.mL\(^{-1}\) for CHL. The IS were added to each concentration level in fixed concentrations of 75 ng.mL\(^{-1}\) sulfaquinoxaline (SPQ) and 200 ng.mL\(^{-1}\) isoniazid (ISZ). The calibration curves were built by weighted 1/x regression analysis of the peak area ratios of the analyte/IS against the analyte/IS nominal concentration. Regression parameters such as the linear equation, slope, intercept, and correlation coefficient (r) were calculated. Variation of up to 15% in the accuracy and precision at each level was allowed, except for LLOQ, for which maximum variations of 20% were permitted.

**Accuracy and precision.** To monitor the performance of the analytical method, accuracy and precision were assessed by analysis of quality control (QC) samples in five replicates at four concentration levels of the analytes, as shown in Table 1. Dilution quality control (DQC) samples were also prepared in quintuplicate, in a manner to obtain concentrations ten times higher than the medium quality controls (MQC). DQC samples were diluted 1:10 (v/v) with blank plasma in order to fit in the calibration curve. After dilution, these samples were processed and analyzed.

### Table 1. Quality control levels used to evaluate method performance.

| Analytes          | LLOQ (ng/mL) | LQC (ng/mL) | MQC (ng/mL) | HQC (ng/mL) | DQC (ng/mL) |
|-------------------|--------------|-------------|-------------|-------------|--------------|
| Chlorpropamide    | 500          | 1000        | 2500        | 3500        | 25000        |
| Glibenclamide     | 125          | 250         | 1000        | 1500        | 10000        |
| Gliclazide        | 50           | 125         | 500         | 750         | 5000         |
| Glimepiride       | 125          | 250         | 1000        | 1500        | 10000        |
| Metformin         | 250          | 500         | 2000        | 3000        | 20000        |
| Nateglinide       | 500          | 1000        | 2000        | 3000        | 20000        |
| Pioglitazone      | 250          | 500         | 1000        | 1500        | 1000         |
| Rosiglitazone     | 125          | 250         | 500         | 750         | 5000         |
| Vildagliptin      | 125          | 250         | 1000        | 1500        | 10000        |

LLOQ, lower limit of quantification; LQC, low quality control; MQC, medium quality control; HQC, high quality control; DQC, dilution quality control.

doi:10.1371/journal.pone.0167107.t001
The intra-day and inter-day accuracies were evaluated over three consecutive days, by calculating the difference between the theoretical and experimental concentrations (relative error, RE%). For this purpose, five replicates of the QC samples were prepared for each analytical run, according to the concentrations shown in Table 1.

Precision was determined by the residual standard deviation (RSD%) at each QC level. The variation of RE% and RSD% should not have exceeded 15%, except for the LLOQ, for which the deviation should not have exceeded 20%.

**Carry-over.** To evaluate the carry-over effect, a blank plasma sample was injected into the chromatographic system, followed by injection of a plasma sample spiked with analyte concentrations of the highest calibration levels. Then, the blank plasma sample was injected two more times. The acceptance criteria was that the responses of the interfering peaks in the blank sample must be less than 5% of the peak area of the ISs and less than 20% of the peak area of the compounds of interest in samples processed at the LLOQ concentration.

**Recovery and matrix effect.** Recovery was measured by comparing plasma samples spiked with analytes and ISs prior to sample clean up with standard solution samples at the same concentration, which represented 100% recovery. This assay was performed in quintuplicate at three levels: LQC, MQC, and HQC (Table 1).

The matrix effect (ME) was assessed by comparing the response obtained from plasma samples to which analytes were added post-extraction (i.e., plasma samples that were submitted to the clean-up procedure prior to addition of the analytes and IS) to standard solution samples at the same concentration. The evaluation of the ME was performed using eight replicates of QC samples at two levels, LQC and HQC (Table 1). For each level, the normalized effect of the matrix (NEM) was assumed as the response of the analyte/IS in the matrix divided by the response of the analyte/IS in the solution. Variations higher than 15% relative to the NEM calculated for all samples suggested the presence of the matrix effect.

**Stability.** The stability tests of compounds of interest and IS in plasma samples were performed under various conditions: benchtop stability (room temperature for 6 h before sample clean up), long-term stability (-40°C for 30 d before sample clean up), processed sample stability (room temperature for 8 h after sample clean up), and freeze and thaw stability (three freeze-thawed cycles at -40°C for 12 h before sample clean up). Plasma stability was evaluated by comparing the response of the analytes and the ISs obtained from the stored samples with the mean values obtained from freshly prepared samples at the same concentration levels (LQC and HQC, Table 1) in triplicate.

The stability of stock solutions (1 mg.mL\(^{-1}\) of each analyte and IS) was determined after 30 d of storage at -40°C, after 6 h at room temperature, and after 72 h at 4°C (1000 ng.mL\(^{-1}\) of each analyte and IS).

Plasma samples were considered stable when the responses were within the 15% range of the nominal value, and standard solution samples were considered stable when the deviation from the theoretical value was less than 10%.

**Ethics statement and volunteer blood collection.** The above method was applied to the plasma samples of diabetic patients and healthy volunteers. Samples of 40 diabetic patients were collected to routine analyses and were donated for this study. Sixteen non-diabetic volunteers participated in the study after signing a written consent form.

In Free and Clarified Consent Term (FCCT) were addressed the objective of the study, possible risks related to the study, the blood collection procedure and place, and informed who was the responsible for the research and gave his telephone and e-mail contact. Moreover, was explained through FCCT that volunteers would not have any responsibility in study expenses and that the no personal information would be disclosed, and only the members of the study would have access to it. After reading and agreeing with the terms, the volunteers signed the FCCT.
Each pair of volunteers received a single dose of one of the following drugs: Diabinese® (chlorpropamide 250 mg), Glibeneck® (glibenclamide 5 mg), Azukon MR® (gliclazide 30 mg), Betes® (glimepiride 4 mg), Metformin Hydrochloride 500 mg, Starlix® (nateglinide 120 mg), Piotaz® (pioglitazone hydrochloride 30 mg), and Galvus® (vildagliptin 50 mg). Diabinese®, Glibeneck®, Azukon MR®, Betes®, and Starlix® were taken before breakfast, and Metformin Hydrochloride, Piotaz®, and Galvus® were taken after breakfast.

Two and a half hours after the oral drug administration, blood samples (3.0 mL) were collected in tubes containing ethylenediaminetetraacetic acid as anticoagulant. All samples were immediately centrifuged at 4,000 rpm for 6.0 min at room temperature, and the plasma was separated and stored at −40˚C before analysis.

Rosiglitazone was not administrated because this drug is not commercially available in Brazil.

The Ethics Committee of Hospital de Clínicas da Universidade Federal do Paraná (Clinics Hospital of the University of Paraná) approved this experimental protocol.

Volunteer plasma sample preparation. The human plasma samples were thawed at room temperature. Aliquots of 200 μL were pipetted into 2 mL polypropylene tubes and spiked with 50 μL of acetonitrile:water (70:30, v/v) and 50 μL of the IS solution to obtain a final concentration of 200 ng mL⁻¹ isoniazid and 75 ng mL⁻¹ sulfaquinoxaline. The samples were placed on a vortex for 1 min. Then, 700 μL of acetonitrile containing 1% formic acid as additive was added, and the mixture was vortexed for 3 min and centrifuged at 14,000 rpm and 4˚C for 10 min to extract the matrix compounds. The supernatants were diluted with water (1:2, v/v) and injected into the analytical system.

Results and discussion
Method development

The first step in method development was the optimization of spectrometry parameters by injecting CHL, GBC, GCZ, GMP, MET, NAT, PIO, ROS, VDP, and ISs (isoniazid and sulfaquinoxaline) individually into the mass spectrometer. In this phase, the ESI source parameters were adjusted to achieve the best signal intensities and signal stabilities for all analytes and ISs. Positive ionization mode was chosen because the analytes had functional groups that readily accept a proton [H⁺], such as amines, amides, and esters (Fig 1). Formic acid, ammonium formate, and combinations of the two were tested as ionization enhancers, and 0.1% formic acid was selected because it provided the highest signal intensities for all nine analytes and both ISs.

Regarding the chromatographic method, columns with different polarities were tested (C8, C18, and cyano columns). The Acquity UPLC® HSS Cyan column (100 x 2.1 mm, 1.8 μm) was chosen because it separated all the drugs used in the study with baseline resolution. When analytes with substantial differences in polarity are analyzed in a single run, a stationary phase with an intermediate polarity (such as a cyano column) is usually a better choice. For instance, in this study we looked at metformin, which is highly polar (Kow = −2.64), and glibenclamide, which is substantially nonpolar (Kow = 4.79) [32]. Different mobile phase compositions were tested using water and acetonitrile or methanol, all containing 0.1% formic acid. Acetonitrile was chosen as the organic modifier because it provided better ionization of the analytes than methanol. The gradient elution was chosen to approximate the analytes’ retention time, improve peak resolution, and reduce run time. Desolvation gas temperature and flow, cone gas flow, column temperature, and injection volume were also optimized. The chromatogram obtained under the defined conditions is shown in Fig 2, with mass error under 5 ppm.

Of all the methods found in the literature that were validated to quantify oral antidiabetic agents in human plasma [30–56], this method is the only one that encompasses nine drugs.
from five different classes in a very short run time, with only 4.5 min for chromatographic separation and 2 min for cleaning of the column and re-equilibration to initial conditions. The use of UPLC instead of HPLC results in a fast analysis. Because the UPLC system withstands higher pressures, it is compatible with stationary phases with a reduced particle size and length, which generates high chromatographic efficiency in a shorter run time. Only two other studies have employed UPLC systems for the quantification of oral antidiabetic agents in plasma [39, 54], but only five analytes were analyzed in each study, from just one [54] and two therapeutic classes [39].

Sample cleanup

Protein precipitation (PP) was chosen as the extraction procedure because it is a simple, fast, and cheap technique. Furthermore, the antidiabetic agents in the study have different polarities and PP is compatible with both hydrophilic and hydrophobic compounds simultaneously. Four precipitant agents were tested: acetonitrile, acetonitrile with 0.1% formic acid, methanol, and methanol with 0.1% formic acid. The highest rates of recovery of analytes and reproducible results were obtained with acetonitrile with 0.1% formic acid.

Method validation

**Limit of detection (LOD) and lower limit of quantification (LLOQ).** The present method proved to be highly sensitive, as demonstrated by the low LODs of 1.25 ng.mL⁻¹ for GBC, GCZ, PIO, ROS, and VDP; 2.5 ng.mL⁻¹ for GMP and MET; 5 ng.mL⁻¹ for NAT; and 10 ng.mL⁻¹ for CHL. The LLOQs were estimated to be 5.0 ng.mL⁻¹ for GCZ; 12.5 ng.mL⁻¹ for GBC, GMP, ROS, and VDP; 25.0 ng.mL⁻¹ for MET and PIO; and 50.0 ng.mL⁻¹ for CHL and...
NAT. The LLOQ values were established as the expected values for therapeutic monitoring studies [21–28].

**Selectivity.** The method was demonstrated to be selective, as no interfering peaks appeared in the retention times of the analytes and ISs in blank, hemolyzed, or lipemic plasma (Fig 3).

**Calibration curve.** Calibration curves obtained in plasma were linear with the correlation coefficients ($r$) $>0.99$. The slope, intercept, and correlation coefficients of each analyte are demonstrated in Fig 4. At all levels, RE% and RSD% deviated less than 15%. Hence, the results are in agreement with the recommendations of the guidelines.

**Accuracy and precision.** The method was accurate and precise for all analytes and ISs, with REs and RSDs of less than 15.0% for both intra- and inter-day analyses. The assays also showed that diluted samples exhibited similar accuracy and precision to the undiluted samples. The results for accuracy and precision are displayed in Table 2.

**Carry-over.** The responses of interfering peaks observed at the retention times of the analytes and ISs in the blank injected right after the highest calibration level were less than 20% and 5%, respectively. Therefore, no carry-over effect was observed between injections.

Fig 3. Selectivity study: Chromatograms of antidiabetic agents overlapping blank plasma chromatograms. (A) chlorpropamide; (B) glibenclamide; (C) gliclazide; (D) glimepiride; (E) metformin; (F) nateglinide; (G) pioglitazone; (H) rosiglitazone; (I) vildaglpirit; (J) isoniazid (IS); and (K) sulfadimethoxine (IS).

doi:10.1371/journal.pone.0167107.g003
Recovery and matrix effect. The individual extraction recoveries and matrix effect data are shown in Table 3. The recovery rates ranged from 61.30 to 86.54%, with RSDs of less than 10%. Therefore, the extraction method using acetonitrile containing 0.1% formic acid can be considered effective and robust for extracting oral antidiabetic agents from human plasma.

The normalized effect of the matrix exhibited coefficient variation below 15%, demonstrating that other components of the sample do not interfere with the analysis.

Stability. The stability tests proved that the analytes and ISs were stable in the biological matrix for 6 h at room temperature (bench-top stability), for 30 d at -40˚C (long-term stability), for 8 h in the sample manager at room temperature (processed sample stability), and after three freeze–thaw cycles (12 h-long cycles at -40˚C). Moreover, the assays showed that the working standard solutions of the analytes and ISs were stable for 6 h at room temperature (25˚C), and for 72 h at 4˚C. The compounds were stable in the stock solutions for 28 d at -40˚C.

Method application

The developed UPLC-QToF-MS method was successfully applied to real plasma samples from diabetic patients from the Clinics Hospital of Paraná, and to samples from healthy volunteers who received an oral dose of one of the drugs in the study. The linear equations and correlation coefficients obtained during sample analyses are demonstrated in S1 Fig. Moreover, all QC levels exhibited deviations of less than 15.0%. The concentrations of drugs in plasma samples obtained from patients treated with glibenclamide, gliclazide, glimepiride, metformin, and vildagliptin are summarized in Table 4. These values are in agreement with the therapeutic range and plasma concentrations observed in previous studies [21–28, 31]. The mean plasma concentrations of the analytes observed in volunteers’ samples are summarized in Table 5. These values are in agreement with other results reported in the literature [20, 29, 30].

The results indicate the high robustness and selectivity of the method, as well as its capability to quantify analytes in samples from patients with different metabolic profiles and comorbidities collected at different times. These characteristics reveal that the method can be used for routine analysis for therapeutic monitoring. Therapeutic monitoring allows for individualized drug dosages and personalized medical care. It provides the ideal drug therapy approach for diabetes by considering metabolic variations among patients, as diabetes is a complex...
Table 2. Precision and accuracy of the antidiabetic agents and internal standards obtained in human plasma by the UPLC-QToF method.

| Compound     | Quality control level | Concentration (ng/mL) | Precision Intraday (RSD%) | Accuracy Intraday (RE%) | Precision Interday (RSD%) | Accuracy Interday (RE%) |
|--------------|-----------------------|-----------------------|---------------------------|-------------------------|---------------------------|-------------------------|
| Chlorpropamide | LLOQ 500              | 6.95                  | 3.92                      | 6.74                    | 3.49                      |                         |
|              | LQC 1000              | 8.20                  | 0.54                      | 8.01                    | -3.35                     |                         |
|              | MQC 2500              | 4.61                  | -1.26                     | 6.13                    | 0.82                      |                         |
|              | HQC 3500              | 6.87                  | 3.50                      | 7.40                    | 2.90                      |                         |
|              | DQC 2500              | 4.74                  | 11.11                     | 9.24                    | 6.19                      |                         |
| Glibenclamide | LLOQ 125              | 8.03                  | 5.76                      | 11.02                   | 4.96                      |                         |
|              | LQC 250               | 6.10                  | -1.84                     | 7.61                    | -2.24                     |                         |
|              | MQC 1000              | 4.63                  | -0.02                     | 8.36                    | -6.97                     |                         |
|              | HQC 1500              | 5.83                  | -1.21                     | 9.08                    | 1.62                      |                         |
|              | DQC 10000             | 3.53                  | 11.82                     | 6.43                    | 10.62                     |                         |
| Gliclazide   | LLOQ 50               | 7.64                  | 8.80                      | 7.01                    | 10.02                     |                         |
|              | LQC 125               | 7.92                  | 3.36                      | 4.77                    | -6.66                     |                         |
|              | MQC 500               | 2.81                  | -8.52                     | 4.46                    | -5.29                     |                         |
|              | HQC 750               | 2.55                  | 3.62                      | 3.83                    | 1.88                      |                         |
|              | DQC 5000              | 4.35                  | 6.10                      | 5.66                    | 3.29                      |                         |
| Glimepiride  | LLOQ 125              | -3.74                 | 8.80                      | 11.31                   | 2.82                      |                         |
|              | LQC 250               | -5.69                 | 3.04                      | 7.16                    | 0.42                      |                         |
|              | MQC 1000              | 5.97                  | -1.88                     | 6.82                    | -6.98                     |                         |
|              | HQC 1500              | -1.48                 | 7.71                      | 5.76                    | 3.09                      |                         |
|              | DQC 10000             | 5.81                  | 1.33                      | 7.40                    | -4.10                     |                         |
| Metformin    | LLOQ 250              | 10.41                 | -2.56                     | 11.45                   | -11.44                    |                         |
|              | LQC 500               | 8.86                  | -1.96                     | 10.71                   | 4.73                      |                         |
|              | MQC 2000              | 5.02                  | 10.6                      | 5.19                    | 7.31                      |                         |
|              | HQC 3000              | 6.25                  | -0.01                     | 5.75                    | -1.15                     |                         |
|              | DQC 20000             | 8.92                  | -4.98                     | 9.17                    | -5.08                     |                         |
| Nateglinide  | LLOQ 500              | 1.84                  | -2.32                     | 4.97                    | 2.42                      |                         |
|              | LQC 1000              | 1.82                  | -0.24                     | 5.92                    | -2.90                     |                         |
|              | MQC 2000              | 2.52                  | 1.37                      | 6.16                    | -3.13                     |                         |
|              | HQC 3000              | 2.39                  | -1.58                     | 5.01                    | 2.12                      |                         |
|              | DQC 20000             | 4.15                  | -5.65                     | 7.82                    | -6.21                     |                         |
| Pioglitazone | LLOQ 250              | 4.09                  | -11.11                    | 8.19                    | -10.57                    |                         |
|              | LQC 500               | 5.76                  | 8.96                      | 7.01                    | 6.80                      |                         |
|              | MQC 1000              | 4.78                  | -0.30                     | 8.62                    | 6.68                      |                         |
|              | HQC 1500              | 5.37                  | -3.30                     | 6.63                    | -2.98                     |                         |
|              | DQC 10000             | 5.10                  | 5.75                      | 7.14                    | 3.50                      |                         |
| Rosiglitazone| LLOQ 125              | 10.25                 | -10.82                    | 8.86                    | -11.50                    |                         |
|              | LQC 250               | 9.34                  | 8.40                      | 5.59                    | 7.80                      |                         |
|              | MQC 500               | 6.13                  | 8.08                      | 5.97                    | 5.91                      |                         |
|              | HQC 750               | 9.05                  | -3.48                     | 6.41                    | -2.02                     |                         |
|              | DQC 5000              | 3.72                  | 0.63                      | 4.65                    | 2.26                      |                         |
| Vildagliptin | LLOQ 125              | 6.49                  | -2.72                     | 11.58                   | -2.45                     |                         |
|              | LQC 250               | 8.50                  | -1.12                     | 8.02                    | 0.14                      |                         |
|              | MQC 1000              | 10.53                 | 2.02                      | 9.09                    | 1.27                      |                         |
|              | HQC 1500              | 5.78                  | 4.64                      | 7.83                    | 1.09                      |                         |
|              | DQC 10000             | 11.90                 | -4.50                     | 11.52                   | -3.32                     |                         |
| Isoniazid (IS)| - 200                 | 7.32                  | -0.02                     | 8.24                    | -0.12                     |                         |

(Continued)
pathology that involves many organs and systems. Furthermore, it is known that genetic factors may significantly interfere with plasma distribution of sulfonylurea [57] and metformin [58, 59]. Reitman and Schadt (2007) [60] reported the growing need for personalized medicine for diabetic patients because of large metabolic and genetic differences among individuals.

Table 2. (Continued)

| Compound                | Quality control level | Concentration (ng/mL) | Precision Intraday (RSD%) | Accuracy Intraday (RE%) | Precision Interday (RSD%) | Accuracy Interday (RE%) |
|-------------------------|-----------------------|-----------------------|---------------------------|-------------------------|--------------------------|------------------------|
| Sulfaquinoxaline (IS)   | -                     | 75                    | 11.11                     | 6.20                    | 11.10                    | 1.69                   |

LLOQ, lower limit of quantification; LQC, low quality control; MQC, medium quality control; HQC, high quality control; DQC, dilution quality control IS, internal standard; RE%, relative error; RSD%, relative standard deviation. Intraday analysis, n = 5; interday analysis, n = 15.

doi:10.1371/journal.pone.0167107.t002

Table 3. Recovery and matrix effect of the antidiabetic agents and internal standards.

| Compound           | Quality control level | Concentration (ng/mL) | Recovery (%) | RSD (%) | Matrix effect (NEM%) |
|--------------------|-----------------------|-----------------------|--------------|---------|----------------------|
| Chlorpropamide     | LQC                   | 1000                  | 83.32        | 6.13    | 11.28                |
| MQC                | 2500                  |                       |              |         |                      |
| HQC                | 3500                  |                       |              |         |                      |
| Glibenclamide      | LQC                   | 250                   | 75.33        | 5.35    | 11.24                |
| MQC                | 1000                  |                       |              |         |                      |
| HQC                | 1500                  |                       |              |         |                      |
| Gliclazide         | LQC                   | 125                   | 84.52        | 4.32    | 11.71                |
| MQC                | 500                   |                       |              |         |                      |
| HQC                | 750                   |                       |              |         |                      |
| Glimepiride        | LQC                   | 250                   | 78.43        | 7.64    | 8.86                 |
| MQC                | 1000                  |                       |              |         |                      |
| HQC                | 1500                  |                       |              |         |                      |
| Metformin          | LQC                   | 500                   | 61.60        | 8.82    | 7.53                 |
| MQC                | 2000                  |                       |              |         |                      |
| HQC                | 3000                  |                       |              |         |                      |
| Nateglinide        | LQC                   | 1000                  | 75.05        | 5.76    | 12.78                |
| MQC                | 2000                  |                       |              |         |                      |
| HQC                | 3000                  |                       |              |         |                      |
| Pioglitazone       | LQC                   | 500                   | 79.94        | 1.40    | 5.09                 |
| MQC                | 1000                  |                       |              |         |                      |
| HQC                | 1500                  |                       |              |         |                      |
| Rosiglitazone      | LQC                   | 250                   | 80.95        | 2.57    | 9.09                 |
| MQC                | 500                   |                       |              |         |                      |
| HQC                | 750                   |                       |              |         |                      |
| Vildagliptin       | LQC                   | 250                   | 73.03        | 8.37    | 13.41                |
| MQC                | 1000                  |                       |              |         |                      |
| HQC                | 1500                  |                       |              |         |                      |
| Isoniazid (IS)     | -                     | 200                   | 77.43        | 3.94    |                      |
| Sulfaquinoxaline (IS) | -                     | 75                    | 84.54        | 2.89    |                      |

LQC, low quality control; MQC, medium quality control; HQC, high quality control; IS, internal standard; RSD%, relative standard deviation; NEM, normalized effect of matrix.

doi:10.1371/journal.pone.0167107.t003
In addition, the results showed significant differences among the plasmatic concentrations of volunteers who received the drugs. Although the volunteers were all healthy, received the antidiabetic agents at the same time, and had blood collected in pairs at the same time, metabolic variations caused differences in plasma concentrations of up to 35% after drug administration, as can be seen in Table 5. Through these analyses, we report a real need for therapeutic monitoring of oral antidiabetic agents. Significant variations suggest that despite similar doses, metabolic rates of the drugs may vary among patients. With the aid of plasma quantification, health professionals will have a powerful tool for the establishment of more effective pharmacological treatments with a reduced likelihood of adverse events related to therapy.

Therefore, the present method was proven to be capable of quantifying different oral antidiabetic agents in human plasma from single and multiple doses, and to be suitable for pharmacokinetic, bioavailability, bioequivalence, and therapeutic monitoring studies.

Conclusions

A method using a UPLC-QToF-MS analyzer was developed and validated for simultaneous quantification of chlorpropamide, glibenclamide, gliclazide, glimepiride, metformin, nateglinide, pioglitazone, rosiglitazone, and vildagliptin in human plasma; these drugs represent the main five classes of oral antidiabetic agents available on the market. The new method was proven to be selective, sensitive, linear, accurate, precise, and free of residual and matrix effects. A simple, fast, and reproducible sample preparation method using protein precipitation was also developed. The method was successfully applied to patient samples, and the presence of different antidiabetic agents could be determined. The new method can be considered suitable for pharmacokinetic, bioavailability, bioequivalence, and therapeutic monitoring studies of oral antidiabetic agents.

Supporting Information

S1 Fig. Calibration curve of analytes in plasma sample during method application. (TIF)

S1 Table. Concentrations of the spiking solutions for the standards used to prepare each calibration level and quality control levels. CHL, chlorpropamide; GBC, glibenclamide;
GCZ, gliclazide; GMP, glimepiride; MET, metformin; NAT, nateglinide; PIO, pioglitazone; ROS, rosiglitazone; VDP, vildagliptin.

Acknowledgments

The authors would like to thank the Ministério da Ciência e Tecnologia–MCT, Ministério da Saúde, Conselho Nacional de Desenvolvimento Científico e Tecnológico–CNPq(MCT/CNPq/CT-SAÚDE/MS/SCTIE/DECIT) and Secretaria da Ciência, Tecnologia e Ensino Superior (SETI-PR) for the financial support of laboratory infrastructure.

Author Contributions

Conceptualization: MMF RP LBC.
Data curation: MMF LBC LPL.
Formal analysis: MMF LBC TMGF RP.
Funding acquisition: RP.
Investigation: MMF TMGF.
Methodology: MMF LBC LPL.
Project administration: RP.
Resources: MMF RP.
Software: MMF LBC LPL.
Supervision: MMF TMGF RP.
Validation: MMF LBC LPL.
Visualization: MMF TMGF RP.
Writing – original draft: MMF LPL TMGF.
Writing – review & editing: TMGF RP.

References

1. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet. 2011; 378(9786): 169–81. doi: 10.1016/S0140-6736(11)60614-4 PMID: 21705072
2. Barrett T. Type 2 diabetes mellitus: incidence, management and prognosis. Paediatr Child Health. 2013; 23(4): 163–7.
3. IDF. International Diabetes Federation—DIABETES ATLAS. 7 ed2015 Sep.
4. Klein S, Sheard NF, Pi-Sunyer X, Daly AE, Wylie-Rosett J, Kulkarni KD, et al. Weight Management Through Lifestyle Modification for the Prevention and Management of Type 2 Diabetes: Rationale and Strategies. Diabetes Care. 2004; 27(8): 2067–73. PMID: 15277443
5. Krentz AJ, Bailey CJ. Oral antidiabetic agents: Current role in type 2 diabetes mellitus. Drugs. 2005; 65 (3): 385–411. PMID: 15669880
6. Simonsen G, Cuddihy R, Reader D. International diabetes center treatment of type 2 diabetes glucose algorithm. Diabetes Manag. 2011; 1(2): 175–89.
7. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpleby G, Zimmerman RS, Bailey TS, et al. American Association of Clinical Endocrinologists and American College of Endocrinology–Clinical Practice
Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan– 2015. Endocr Pract. 2015; 21(1): 1–87.

8. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2015; 38(1): S1–S2.

9. Sociedade Brasileira de Diabetes. Conduta Terapêutica no Diabetes Tipo 2: Algoritmo 2015. Posicionamento oficial SBD n°2. 2015: 1–36.

10. Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013; 5(6): 1–15.

11. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future. Lancet. 2014; 383(9922): 1068–83. doi: 10.1016/S0140-6736(13)62154-6 PMID: 24315620

12. Pratley RE. The early treatment of type 2 diabetes. Am J Med. 2013; 126 (1): S2–9.

13. Ovalle F. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes. Clin Ther. 2011; 33(4): 393–407. doi: 10.1016/j.clinthera.2011.04.006 PMID: 21635987

14. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38(1): 140–9. doi: 10.2337/dc14-2441 PMID: 25538310

15. Kang JS, Lee MH. Overview of therapeutic drug monitoring. The Korean journal of internal medicine. 2009; 24(1): 1–10. doi: 10.3904/kjim.2009.24.1.1 PMID: 19270474

16. Garcia-Perez LE, Alvarez M, Dilla T, Gil-Guillen V, Orozco-Beltran D. Adherence to therapies in patients with type 2 diabetes. Diabetes therapy: research, treatment and education of diabetes and related disorders. 2013; 4(2): 175–94.

17. EMA European Medicine Agency. Guideline on bioanalytical method validation. Committee for Medicinal Products for Human Use. 2012; 44(2011): 1–23.

18. Food and Drug Administration. Guidance for Industry. Bioanalytical method validation. 2001.

19. RDC 27 de 17 de maio de 2012: Dispõe sobre os requisitos mínimos para a validação de métodos bioanalíticos empregados em estudos com fins de registro de medicamentos, (2012).

20. Bakare MT, Mustapha A, Abduaguye I. An Improved High-Performance Liquid-Chromatographic Determination of Chlorpropamide in Human Plasma. Chromatogr. 1994; 39(1–2): 107–9.

21. Frid A, Hermansen K, Nauck M, Shah N, Tankova T, Mitha I, et al. Long-term sustained glycaemic control with liraglutide and glimepiride (both plus metformin), with added benefits of weight loss and less hypoglycaemia with liraglutide: 2-year LEAD-2 data. Diabetol. 2009; 52: S8–S.

22. Gedeon C, Kapur B, Alexska K, Koren G. A simple and rapid HPLC method for the detection of glyburide in plasma original research communication (analytical). Clin Biochem. 2008; 41(3): 167–73. doi: 10.1016/j.clinbiochem.2007.07.025 PMID: 18061587

23. He Y-L, Sabo R, Picard F, Wang Y, Herron J, Ligueros-Saylan M, et al. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. Curr Med Res Opin. 2009; 25 (5): 1265–72. doi: 10.1185/03007990902869102 PMID: 19364302

24. He Y-L, Wang Y, Bullock JM, Deacon CF, Holst JJ, Dunning BE, et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol. 2007; 47(5): 633–41. doi: 10.1177/0091270006299137 PMID: 17442688

25. Kawaguchi-Suzuki M, Briol F, Sanchez PP, Cusi K, Frye RF. A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxyproglastazone, and ketopioiglitaone in human plasma and its application to a clinical study. J Chromatogr B. 2014; 969: 219–23.

26. Malli D, Mikhailis E, Vavagiannis A, Kazani S, Daniilides K, Gennimata D, et al. Determination of nateglinide in human plasma by high-performance liquid chromatography with pre-column derivatization using a coumarin-type fluorescent reagent. Anal Chim Acta. 2007; 599(1): 143–50. doi: 10.1016/j.aca.2007.08.004 PMID: 17765074

27. Matsuki M, Matsuda M, Kohara K, Shimoda M, Kanda Y, Tawaramoto K, et al. Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of once- versus twice-daily dosing. Endocr J. 2007; 54(4): 571–6. PMID: 17603225

28. Naraharisetti SB, Kirby BJ, Hebert MF, Easterling TR, Unadkat JD. Validation of a sensitive LC-MS assay for quantification of glyburide and its metabolite 4-transhydroxy glyburide in plasma and urine: An OPRE Network study. J Chromatogr B. 2007; 860(1): 34–41.

29. Odunola MTB, Enemali IS, Garba M, Obodoozie OO. Rapid high performance liquid chromatographic determination of chlorpropamide in human plasma. Afr J Biotechnol. 2007; 6(12): 1378–81.
30. Viana IMD, Lima PDR, Soares CDV, Fernandes C. Simultaneous determination of oral antidiabetic drugs in human plasma using microextraction by packed sorbent and high-performance liquid chromatography. J Pharmaceut Biomed. 2014; 96: 241–8.

31. Yardimci C, Ozaltin N, Gurlek A. Simultaneous determination of rosiglitazone and metformin in plasma by gradient liquid chromatography with UV detection. Talanta. 2007; 72(4): 1416–22. doi: 10.1016/j.talanta.2007.01.042 PMID: 19071778

32. Georgita C, Albu F, David V, Medvedovic A. Simultaneous assay of metformin and glibenclamide in human plasma based on extraction-less sample preparation procedure and LC/(APCI)MS. J Chromatogr B. 2007; 854(1–2): 211–8.

33. Ben-Hander GM, Makahleh A, Saleh MI, Cheng KW. Sequential hollow-fiber liquid phase microextraction for the determination of rosiglitazone and metformin hydrochloride (anti-diabetic drugs) in biological fluids. Talanta. 2015; 131: 590–6. doi: 10.1016/j.talanta.2014.08.037 PMID: 25281145

34. Jingar JN, Rajput SJ, Dasandi B, Rathnam S. Development and validation of LC-UV for simultaneous estimation of rosiglitazone and glimepride in human plasma. Chromatographia. 2008; 67(11–12): 951–5.

35. Ranetti MC, Ionescu M, Hinescu L, Ionica E, Anuta V, Ranetti AE, et al. Validation of a Hplc Method for the Simultaneous Analysis of Metformin and Gliclazide in Human Plasma. Farmacia. 2009; 57(6): 728–35.

36. Rashid A, Ahmad M, Minhas MU, Hassan IJ, Malik MZ. Pharmacokinetic studies of metformin and glibenclamide in normal human volunteers. Pak J Pharm Sci. 2014; 27(1): 153–9. PMID: 24374443

37. Tirimula R, Lakshmi KS. Quantification of gliclazide, glipizide, glimepride, pioglitazone, repaglinide and rosiglitazone in human plasma using reverse-phase high-performance liquid chromatography. J Pharm Pharmacol. 2009; A102–A3.

38. Attimarad MV, Nair AB, Alidhubaibe B. Development of liquid chromatographic method for the simultaneous determination of metformin and miglitol in human plasma: application to pharmacokinetic studies. J Iran Chem Soc. 2015; 12(9): 1629–36.

39. Binz TM, Villani N, Neels H, Schneider S. Rapid extraction, identification and quantification of oral hypoglycaemic drugs in serum and hair using LC-MS/MS. Forensic Sci Int. 2012; 223(1–3): 119–24. doi: 10.1016/j.forsciint.2012.08.014 PMID: 22940189

40. Chen L, Zhou Z, Shen M, Ma A. Simultaneous determination and pharmacokinetic study of metformin and rosiglitazone in human plasma by HPLC-ESI-MS. J Chromatogr Sci. 2011; 49(2): 94–100. PMID: 21223632

41. Hess C, Musshoff F, Madea B. Simultaneous identification and validated quantification of 11 oral hypoglycaemic drugs in plasma by electrospray ionisation liquid chromatography-mass spectrometry. Anal Bioanal Chem. 2011; 400(1): 33–41. doi: 10.1007/s00216-011-4698-8 PMID: 21327875

42. Hoizy G, Lamiable D, Trenque T, Robinet A, Binet L, Kaltenbach ML, et al. Identification and quantification of 8 sulfonylureas with clinical toxicology interest by liquid chromatography-ion-trap tandem mass spectrometry and library searching. Clin Chem. 2005; 51(9): 1666–72. doi: 10.1373/clinchem.2005.050864 PMID: 16020498

43. Jagadeesh B, Bharathi DV, Pankaj C, Narayana VS, Venkateswarulu V. Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: Application to a pharmacokinetic study. J Chromatogr B. 2013; 930: 136–45.

44. Li N, Deng Y, Qin F, Yu J, Li FM. Simultaneous quantification of metformin and glipizide in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. Biomed Chromatogr. 2013; 27(2): 191–6. doi: 10.1002/bmc.2768 PMID: 22763773

45. Lin ZJ, Desai-Krieger D, Shum L. Simultaneous determination of glipizide and rosiglitazone unbound drug concentrations in plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyst Technol Biomed Life Sci. 2004; 801(2): 265–72. PMID: 14751795

46. Magni F, Marazzini L, Pereira S, Monti L, Galli Kienle M. Identification of sulfonylureas in serum by electrospray mass spectrometry. Anal Biochem. 2000; 282(1): 136–41. doi: 10.1006/abio.2000.4597 PMID: 10860510

47. Maurer HH, Kratzsch C, Kraemer T, Peters FT, Weber AA. Screening, library-assisted identification and validated quantification of oral antidiabetics of the sulfonylurea-type in plasma by atmospheric pressure chemical ionization liquid chromatography-mass spectrometry. J Chromatogr B. 2002; 773(1): 63–73.

48. Ding CG, Zhou Z, Ge QH, Zhi XJ, Ma LL. Simultaneous determination of metformin and glipizide in human plasma by liquid chromatography-tandem mass spectrometry. Biomed Chromatogr. 2007; 21(2): 132–8. doi: 10.1002/bmc.723 PMID: 17221919
49. Mistri HN, Jangid AG, Shrivastav PS. Liquid chromatography tandem mass spectrometry method for simultaneous determination of antidiabetic drugs metformin and glyburide in human plasma. J Pharmaceut Biomed. 2007; 45(1): 97–106.

50. Ni XJ, Wang ZZ, Shang DW, Zhang M, Hu JQ, Qiu C, et al. Simultaneous determination of glimepiride and pioglitazone in human plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study. J Chromatogr B. 2014; 960: 247–52.

51. Pontarolo R, Gimenez AC, de Francisco TMG, Ribeiro RP, Fontes FLD, Gasparetto JC. Simultaneous determination of metformin and vildagliptin in human plasma by a HILIC-MS/MS method. J Chromatogr B. 2014; 965: 133–41.

52. Reddy S, Ahmed I, Ahmad I, Mukhopadhay A, Thangam S. Development and Validation of a Method for Simultaneous Estimation of Metformin and Sitagliptin in Human Plasma by LC-MS-MS and Its Application in a Bioequivalence Study. J Chromatogr Sci. 2015; 53(9): 1549–56. doi: 10.1093/chromsci/bmv055 PMID: 25987553

53. Sengupta P, Bhaumik U, Ghosh A, Sarkar AK, Chatterjee B, Bose A, et al. LC-MS-MS Development and Validation for Simultaneous Quantitation of Metformin, Glimepiride and Pioglitazone in Human Plasma and Its Application to a Bioequivalence Study. Chromatographia. 2009; 69(11–12): 1243–50.

54. Shantikumar S, Satheshkumar N, Prasanth B, Lingesh A, Paul D, Srinivas R. A sensitive and selective liquid chromatography mass spectrometry method for simultaneous estimation of anti-diabetic drugs inhibiting DPP-4 enzyme in human plasma: overcoming challenges associated with low recovery and sensitivity. Anal Methods-Uk. 2015; 7(15): 6198–206.

55. Zhang L, Tian Y, Zhang Z, Chen Y. Simultaneous determination of metformin and rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: Application to a pharmacokinetic study. J Chromatogr B. 2007; 854(1–2): 91–8.

56. Zhong GP, Bi HC, Zhou SF, Chen X, Huang M. Simultaneous determination of metformin and gliclazide in human plasma by liquid chromatography-tandem mass spectrometry: application to a bioequivalence study of two formulations in healthy volunteers. J Mass Spectrom. 2005; 40(11): 1462–71. doi: 10.1002/jms.907 PMID: 16255063

57. Sesti G, Laratta E, Cardellini M, Andreozzi F, Del Guerra S, Irace C, et al. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. The Journal of clinical endocrinology and metabolism. 2006; 91(6): 2334–9. doi: 10.1210/jc.2005-2323 PMID: 16595597

58. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007; 117(5): 1422–31. doi: 10.1172/JCI30558 PMID: 17476361

59. Shikata E, Yamamoto R, Takane H, Shigemasa C, Ikeda T, Otsubo K, et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet. 2007; 52(2): 117–22. doi: 10.1007/s10038-006-0087-0 PMID: 17111267

60. Reitman ML, Schadt EE. Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest. 2007; 117(5): 1226–9. doi: 10.1172/JCI32133 PMID: 17476355